JAPAN TISSUE ENGINEERING CO., LTD. Japan Tissue Engineering Co., Ltd. Stock
Equities
7774
JP3389610001
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 653 JPY | -1.21% |
|
+0.62% | +29.05% |
| Sales 2024 * | 2.83B 18.29M | Sales 2025 * | 4.39B 28.38M | Capitalization | 26.84B 173M |
|---|---|---|---|---|---|
| Net income 2024 * | 95M 614K | Net income 2025 * | 959M 6.2M | EV / Sales 2024 * | 9.48 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.11 x |
| P/E ratio 2024 * |
287
x | P/E ratio 2025 * |
28
x | Employees | 215 |
| Yield 2024 * |
1.51% | Yield 2025 * |
-
| Free-Float | 27.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.21% | ||
| 1 week | +0.62% | ||
| Current month | -4.39% | ||
| 1 month | +4.31% | ||
| 3 months | +30.08% | ||
| 6 months | +28.80% | ||
| Current year | +29.05% |
1 week
629.00
684.00
1 month
623.00811.00
Current year
482.00811.00
1 year
472.00811.00
3 years
451.00859.00
5 years
447.001 031.00
10 years
447.001 977.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ken-ichiro Hata
PSD | President | 59 | 04-09-30 |
Masukazu Iie
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | 67 | 07-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Toshihiro Osuka
BRD | Director/Board Member | 67 | 99-01-31 |
Ken-ichiro Hata
PSD | President | 59 | 04-09-30 |
Yukio Mori
CTO | Chief Tech/Sci/R&D Officer | 63 | 04-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 653 | -1.21% | 29 700 |
| 24-04-22 | 661 | +2.48% | 60,300 |
| 24-04-19 | 645 | -5.43% | 79,600 |
| 24-04-18 | 682 | +3.18% | 60,400 |
| 24-04-17 | 661 | +1.85% | 56,700 |
Delayed Quote Japan Exchange, April 23, 2024 at 02:00 am EDT
More quotes
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Calendar
2024-04-29
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.05% | 173M | |
| +9.42% | 125B | |
| -8.50% | 10.48B | |
| -3.67% | 8.42B | |
| +10.71% | 6.82B | |
| +24.48% | 4.96B | |
| +7.41% | 3.41B | |
| -0.91% | 3.04B | |
| -10.69% | 2.1B | |
| -11.48% | 1.97B |
- Stock Market
- Equities
- 7774 Stock
